Review of bimekizumab in the treatment of psoriasis

• Główni autorzy: Sindhuja Koppu (Autor), Rohan Singh (Autor), Kiranjit Kaur (Autor), Steven R. Feldman (Autor)
• Format: Książka
• Wydane: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Bimekizumab, a selective interleukin (IL) 17 inhibitor, is an emerging systemic treatment for moderate-to-severe psoriasis. Although IL-19, IL-22, and IL-36 are implicated in the pathogenesis of psoriasis, IL-17 drives the activation of these interleukins and the formation of psoriatic plaques. This...